In this study, we aim to explore the optimal modified criteria based on radiological criteria (RECIST 1.1, mRECIST) and oncological characteristics (e.g., baseline AFP and AFP change) to assess tumor response for uHCC receiving conversion-radiotherapy before hepatectomy based on recurrence-free survival (RFS). This evidence concerns the gene AFP and neoplasm.